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Abstract
Influenza infection stimulates protective host immune responses but paradoxically enhances lung indoleamine 2,3
dioxygenase (IDO) activity, an enzyme that suppresses helper/effector T cells and activates Foxp3-lineage regulatory CD4 T
cells (Tregs). Influenza A/PR/8/34 (PR8) infection stimulated rapid elevation of IDO activity in lungs and lung-draining
mediastinal lymph nodes (msLNs). Mice lacking intact IDO1 genes (IDO1-KO mice) exhibited significantly lower morbidity
after sub-lethal PR8 infection, and genetic or pharmacologic IDO ablation led to much faster recovery after virus clearance.
More robust influenza-specific effector CD8 T cell responses manifested in lungs of PR8-infected IDO1-KO mice, though virus
clearance rates were unaffected by IDO ablation. Similar outcomes manifested in mice infected with a less virulent influenza
A strain (X31). IDO induction in X31-infected lungs was dependent on IFN type II (IFNc) signaling and was restricted to non-
hematopoietic cells, while redundant IFN type 1 or type II signaling induced IDO exclusively in hematopoietic cells from
msLNs. Memory T cells generated in X31-primed IDO1-KO mice protected mice from subsequent challenge with lethal doses
of PR8 (1006LD50). However recall T cell responses were less robust in lung interstitial tissues, and classic dominance of TCR
Vb8.3 chain usage amongst memory CD8+ T cells specific for influenza nucleoprotein (NP366) did not manifest in IDO1-KO
mice. Thus, influenza induced IDO activity in lungs enhanced morbidity, slowed recovery, restrained effector T cell responses
in lungs and shaped memory T cell repertoire generation, but did not attenuate virus clearance during primary influenza A
infection.
Citation: Huang L, Li L, Klonowski KD, Tompkins SM, Tripp RA, et al. (2013) Induction and Role of Indoleamine 2,3 Dioxygenase in Mouse Models of Influenza A
Virus Infection. PLoS ONE 8(6): e66546. doi:10.1371/journal.pone.0066546
Editor: Mauricio Martins Rodrigues, Federal University of Sa˜o Paulo, Brazil
Received February 27, 2013; Accepted May 7, 2013; Published June 13, 2013
Copyright:  2013 Huang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding to support this study was provided via a U01 grant (AI-83005) awarded to ALM and RAT from the National Institutes of Health/National
Institute of Allergy and Infectious Diseases Immune Mechanisms of Virus Control (IMVC) Program. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflict. David Munn and Andrew Mellor serve as members of the
Scientific Advisory Board of NewLink Genetics Inc and receive remuneration from this source for this service. They are full-time members of Georgia Regents
University and not employees of NewLink Genetics Inc. The service they provide to NewLink Genetics Inc. does not alter the adherence to all the PLOS ONE
policies on sharing data and materials as detailed in the guide for authors.
* E-mail: amellor@gru.edu
. These authors contributed equally to this work.
Introduction
Cells expressing IDO suppress innate and adaptive immunity in
a range of clinically relevant syndromes including autoimmune,
allergic and infectious diseases, cancer, pregnancy, and transplan-
tation [1]. IDO expressed at local sites of chronic inflammation
caused by tumors and some persistent infections suppresses natural
and vaccine-induced immunity to allow these agents of disease to
persist in immunocompetent individuals, despite the antigenicity of
tumor cells and infected cells [2,3,4]. In 1979 Yoshida and
colleagues reported that influenza A virus (PR8) infection up-
regulated IDO enzyme activity rapidly in mouse lung homoge-
nates, peaking at ,120-fold over basal levels in uninfected lungs
when viral burdens were decreasing due to host adaptive
immunity [5]. The role of IDO during primary host responses
to influenza infection has not been defined, but elevated IDO
activity due to prior influenza infection interfered with host control
of subsequent Streptococcus pneumoniae lung infections as treatment
with the reversible IDO inhibitor 1-methyl-tryptophan (1MT) led
to significant reduction in bacterial outgrowth in lungs and to
reduced levels of IL-10 and TNFa [6]. Thus, IDO induced by
primary influenza infection impedes host control of secondary
bacterial lung infections, a major cause of patient mortality after
influenza infection [7].
Tissue inflammation elevates IDO activity because IFNs
(IFNab, IFNc) stimulate IDO gene transcription, though poorly
defined post-translational processes are also essential for IDO
enzyme activity. Hematopoietic myeloid cells and non-hemato-
poietic (stromal) cells can express IDO at inflammatory lesions.
IDO activity induced in inflamed lymph nodes (LNs) draining sites
of tumor growth, and following topical exposure to a tumor
promoter (phorbol ester) conferred dominant IDO-dependent
regulatory phenotypes on DCs in dLNs [8,9]. Splenic CD19+ DCs
also expressed IDO and mediated IDO-dependent T cell
suppression when mice were treated with soluble CTLA4
(CTLA4-Ig), relatively high doses of TLR9 ligands (CpG
oligonucleotides) and DNA nanoparticles delivered systemically
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[10,11,12,13,14,15]. In these and other settings of inflammation,
induced IDO activity in DCs caused naı¨ve CD4 T cells to convert
into Foxp3-lineage regulatory T cells (Tregs) and stimulated pre-
formed, resting Tregs to acquire potent regulatory phenotypes that
attenuated effector T cell responses [16,17,18,19]. Tumor cells
and some stromal cell types such as epithelial cells and fibroblasts
can also express IDO at sites of inflammation, and these cells may
also promote local T cell regulation.
In the current study we investigated the role and mechanism of
IDO induction in two murine models of influenza A infection
using strain PR8 and the less virulent strain X31 by monitoring
IDO induction in lungs and draining LNs and evaluating the
consequences of ablating IDO1 genes, one of two homologous
genes (IDO1 and IDO2) that encode IDO [20,21], on the course
of host primary and recall T cell responses to influenza infection.
Materials and Methods
Virus
Stocks of HKx31 (H3N2) (X31) and A/PR/8/34 (PR8)
influenza virus were propagated in embryonated chicken eggs.
Titers for X31 virus and PR8 virus were 1.56107 PFU/ml and
1.46107 PFU/ml respectively. Virus titers in tissues from infected
mice were measured as 50% tissue culture infection dose (TCID50)
using MDCK cells as described [22]. 50% lethal dose (mLD50) of
PR8 virus was estimated using 6 to 8 week old WT female mice;
30% weight drop was used as the experimental endpoint.
Mice and infections
All animal procedures were approved by the GRU animal usage
committee (IACUC, AUP#2009-0052). C57BL/6 (B6) mice were
purchased from Jackson Lab (Bar Harbor, Maine) or the National
Cancer Institute (Frederick, MD) or bred at GRU. All genetically
engineered mice were crossed onto the B6 background for at least
10 generations. IDO1-KO mice were described previously [23];
IFNcR1-KO mice were purchased (Jax Labs); IFNAR-KO mice
were a kind gift from Dr. Dimitrious Moskophidis [24]. Mice were
infected with influenza virus diluted in PBS with 0.1% endotoxin-
free, Ig-free BSA (Gemini Bio-products, Calabasas, California) via
intranasal inoculation. Mice were anesthetized with isofluorane
prior to inoculation. A dose of 30% of mLD50 PR8 virus was used
for sub-lethal primary infection and a dose of 1006mLD50 PR8
virus was used to challenge X31 primed mice to test for protection
against lethal infection afforded by memory T cells. For infection
induced morbidity experiments, WT and IDO1-KO mice with
BALB/c or B6 genetic backgrounds (fully backcrossed) were
infected with PR8 virus (30% of mLD50) and mice were weighed
daily Comparable outcomes were obtained for mice with both
genetic backgrounds (data not shown). To generate bone marrow
chimeric mice, IDO1-KO mice were lethally irradiated (900 rad),
injected (i/v) with 16107 nucleated bone marrow cells by tail vein
injection. Recipient mice were allowed to reconstitute for .6
weeks before infection.
Antibodies, peptides and tetramers
Fluorophore conjugate anti-mouse CD4 (clone GK1.5 or RM4-
5), CD8 (clone 53.67), Ly6G (clone 1A8), Ly6C (clone HK1.4),
IFNc (clone XMG1.2), were obtained from BD Bioscience (San
Jose, CA), eBioscience (San Diego, CA) or Biolegend (San Diego,
CA). Mouse anti-human and mouse anti-IDO1 monoclonal
antibodies (E7) were from Santa Cruz Biotechnology, and rat
anti-mouse IDO1 monoclonal antibody (mIDO48) was from
Biolegend. Mouse anti-influenza NP (ATCC clone H16-L104R5)
antibody was purified from culture supernatant and biotinylated
using NHS-biotin according to manufacturer’s instructions
(Pierce/Thermo, Rockford, IL). A mouse anti-TCR Vb mAb
screening panel (BD Biosciences, CA) was used to type TCR Vb
chains in NP366-specific T cells.
Peptides specific to H-2Db restricted NP366, H-2D
b restricted
PA, H-2Kb restricted PB1 and H-2IAb restricted NP311 were
synthesized at Biobasic (Toronto, Canada). MHC class I tetramers
were prepared in house as described [24,25]. MHC class I
monomers were biotinylated using biotin ligase BirA (Avidity,
Aurora, Co). Biotinylated monomers were coupled to PE-
conjugated streptavidin (Invitrogen, Calsbad, CA) to form
tetramers. MHC class II tetramers were acquired from the
NIH/NIAID core facility. Cell-surface stainings for flow cytom-
etry analysis were performed in PBS with 0.1% BSA except for
MHC class II tetramers, when HBSS was used instead of PBS.
Bronchoalveolar Lavage (BAL)
BAL samples were collected by inserting a catheter into a small
opening in the trachea and then flushing the lung with PBS 3
times. BALs from individual mice were analyzed. Lung interstitial
cells were extracted as described with minor modifications [26].
Briefly, mice were perfused with PBS (6 ml) via the right ventricle
after BAL extraction. Lungs were digested in 400 U/ml type 4
collagenase (Worthington Biochemical, Lakewood, NJ), and cells
released were centrifuged in 40% Percoll. For intracellular
cytokine staining, cells were placed in 96 well plates and stimulated
ex vivo with appropriate peptide plus brefeldin (3 mg/ml,
eBioscience) and 5 U/ml hIL2 (Roche Bioscience, Palo Alto,
CA) for 4 hours. For stimulation of CD8 T cells from BAL and
lung, V-bottom plates were used to provide better cell contact. For
stimulation of CD4 T cells from BAL and lung, V-bottom plates
were used and 50,000 spleen cells from Thy1.1 mice were added
as feeders. Cells were then surface stained with anti-mouse CD8 or
CD4, fixed with Perm/Fix (BD bioscience) and stained to detect
intracellular IFNc and IL10. To detect total Th1 and Th17 cells T
cells isolated from BAL and lung parenchyma were stimulated ex
vivo with 100 ng/ml PMA+1.5 mM ionomycin plus brefeldin.
Flow cytometry
Cells were analyzed on a FACS LSRII flow cytometer. DAPI
was added prior to analysis tetramer stained samples to identify
dead cells. Data were analyzed using FACS DIVA (BD Bioscience)
or FlowJo (Tree Star, Ashland, OR) software.
Immunohistochemistry and Western blotting
For immunohistological analysis, lungs were infused with 20%
OCT diluted in PBS and snap frozen in isopentane/dry ice bath.
Nonspecific staining was blocked using 2% BSA and endogenous
biotin was blocked using a biotin/avidin blocking kit (Vectorlabs,
Burlingame, CA). A mouse monoclonal anti-mouse/human IDO
antibody (5 mg/ml, E7, Santa Cruz Biotechnology) was used on
methanol fixed lung frozen sections to detect IDO using a M.O.M
kit (Vectorlabs, Burlingame, CA). Biotinylated anti-NP antibody
was used at a concentration of 10 mg/ml. For western blotting,
protein concentrations in tissue homogenates were measured using
Bradford reagent (Pierce/Thermo, Rockford, IL). IDO protein
was detected using monoclonal rat anti-mouse IDO1 antibody
(mIDO48) using a chemiluminescent reagent (Denville Scientific,
South Plainfield, NJ).
Tissue kynurenine and IDO activity
Snap frozen tissues were homogenized in PBS at concentrations
of 100 mg/ml (lung) and 50 mg/ml (lymph nodes). Kynurenine
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(Kyn) and tryptophan (Trp) were measured by HPLC after de-
proteination using a C18 reverse phase column [27]. Tissue Kyn
was expressed as pmol/mg tissue and serves as an in vivo index of
IDO enzyme activity. IDO enzyme activity in cell-free tissue
homogenates (in situ) was measured as described [28]. IDO activity
was calculated as pmol kynurenine/hr/mg tissue.
Results
Influenza PR8 infection induces IDO activity in lungs and
mediastinal lymph nodes (msLNs)
To evaluate IDO enzyme activity during influenza infection B6
mice were infected with sub-lethal doses (50 PFU/mouse, i/n) of
influenza A/PR/8/34 (PR8) virus and levels of the tryptophan
catabolite kynurenine (Kyn) released by cells expressing functional
IDO enzyme activity were assessed in lungs and msLNs by
performing HPLC analysis on tissue homogenates. Kyn levels
were elevated significantly in PR8-infected lungs, relative to basal
levels in uninfected lungs, from 3–5 days post infection (dpi), and
Kyn levels continued to increase until.10 dpi (Fig. 1A). Increased
Kyn levels were also detected in msLNs starting slightly later (5–
7 dpi) after infection (Fig. 1B). No kynurenine was detected in
lungs or msLNs of IDO1-deficient (IDO1-KO) mice with B6
backgrounds (Fig. 1AB, open symbols), indicating that induced
IDO enzyme activity is encoded by IDO1, not IDO2 [20,21].
These data confirm and extend previous studies showing dramatic
increases in lung IDO activity induced by PR8 infection [5].
IDO enhances morbidity following PR8 infection
Sub-lethal infection of BALB/c mice with PR8 induced
progressive reduction in body weight peaking at ,20% weight
loss at 11 dpi (relative to initial body weights) followed by gradual
recovery (Fig. 1C, closed symbols). Sub-lethal PR8 infection
caused significantly lower morbidities in BALB/c mice lacking
intact IDO1 genes (IDO1-KO mice) as peak weight loss was
,13%. Moreover, recovery from influenza began earlier and
progressed faster in IDO1-KO mice (Fig. 1C, open symbols). Oral
treatment (ad libitum) of BALB/c mice with the IDO-specific
inhibitor 1-methyl-[D]-tryptophan (D1MT) during PR8 infection
had no effect on morbidity induction but mice recovered weight
much faster following viral clearance (Fig. 1D). At 7 dpi, when
sterile PR8 clearance occurred in this model, lung weights were
significantly higher (20–25%) in PR8-infected IDO1-KO mice
relative to WT (BALB/c) controls (Fig. 1E), indicating that
inflammatory infiltrates were more robust in IDO1-KO mice.
However, no significant differences in lung viral burdens were
detected during infection (Fig. 1F). Comparable disparities in PR8
induced morbidity and recovery rates after virus clearance were
observed using WT and IDO1-KO with B6 backgrounds (data not
shown), indicating that this phenomenon was not strain-specific.
Thus, induced host IDO activity in PR8-infected lungs drives
higher morbidity and slows recovery following primary influenza
infection.
IDO ablation enhances influenza-specific CD8 T cell
responses to primary PR8 infection
To assess if IDO1 gene ablation affected primary T cell
responses to PR8 infection IDO1-KO mice with B6 backgrounds
were infected with sub-lethal doses of PR8 (50 PFU/mouse, i/n)
and virus-specific T cell responses were evaluated (at 10 dpi) by
staining bronchial alveolar lavage (BAL) cells with anti-CD8 mAbs
plus MHC class I tetramer reagents that bind to T cells specific for
influenza nucleoprotein NP366, PA, or PB1 epitopes, and anti-
CD4 mAbs plus MHC class II tetramer reagents specific to NP311
and analyzing cells by flow cytometry using the representative
gating strategy shown for NP366-specific CD8 T cells (Fig. 2A).
Numbers of cells and CD8+ T cells were significantly higher in
BAL from PR8-infected IDO1-KO mice, relative to WT control
mice (Fig. 2B). More influenza NP- and PA-specific BAL CD8+ T
cells were present, and higher proportions of these cells expressed
intracellular IFNc and IL-10 in PR8-infected IDO1-KO mice
(Fig. 2C and D). Small increases in PB1-specific CD8+ T cells
(Fig. 2E), total CD4+ (Fig. 2B) and NP311-specific CD4
+ T cells
(Fig. 2F) were observed in BAL of PR8-infected IDO1-KO mice,
but these increases were not statistically significant. Thus more
robust influenza-specific effector CD8+ T cell (CTL) responses
manifested in mice lacking intact IDO1 genes, indicating that
influenza-induced IDO activity attenuates clonal expansion and/
or inhibits access of CTLs into infected lungs of IDO-sufficient
mice.
Influenza infection stimulates increased IDO enzyme
activity in lungs and msLNs
As sub-lethal PR8 infection caused substantial differences in
morbidity between WT and IDO1-KO mice (Fig. 1), we used a
less virulent strain (X31) to evaluate the role of IDO in host-
Figure 1. IDO increases morbidity and slows recovery in PR8-
infected mice. B6 (WT) or IDO1-KO mice were infected with PR8 virus
(50 PFU, i/n). AB. Tissue kynurenine (Kyn) in lung homogenates (A) and
IDO enzyme activity in msLN homogenates (B) were estimated by HPLC.
CD. Morbidity was assessed by monitoring weight loss after infection
(normalized to initial weights) in BALB/c (WT), IDO1-KO (C) and BALB/c
(WT) mice given oral D1MT during infection (D). EF. Lung weights (E)
and lung virus loads (F) were also evaluated. Data are the means (+/
21sd) of .3 mice/group from at least two independent experiments
unless otherwise stated in the figure. **p,0.01, ****p,0.0001.
doi:10.1371/journal.pone.0066546.g001
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pathogen interactions. B6 mice were infected with relatively low
doses of X31 (750 PFU/mouse) that did not cause significant
morbidity (data not shown), and Kyn levels were detected in lung
homogenates from X31-infected mice. Similar to PR8-infected
mice, Kyn levels in lungs from X31-infected WT mice increased
from 3–6 dpi and peaked at 7–8 dpi (Fig. 3A). Kyn levels declined
slowly after 8 dpi but did not return to basal levels by .11 dpi,
even though sterile virus clearance occurred in lungs by 7 dpi
(Fig. 4C). As Kyn is excreted rapidly, these data indicate that
influenza-induced IDO activity remained abnormally high in
lungs for a long time after virus was eliminated. As expected, lung
Kyn levels were below detection limits during primary infection
and after viral clearance in X31-infected IDO1-KOmice (Fig. 3A).
To evaluate if IDO activity was also induced in msLNs cell-free
homogenates of msLNs were incubated with enzyme substrate
cocktail for 2 hours and Kyn generated ex vivo was assessed by
HPLC as described in Materials and Methods. Similar to Kyn
levels in lungs, IDO activity in msLNs increased substantially
between 3 dpi and 8 dpi, while no IDO activity was detected in
msLNs of X31-infected IDO1-KO mice (Fig. 3B). Consistent with
these findings, IDO protein expression was substantially higher in
lungs of X31-infected mice from 6–10 days post-infection and
remained higher than basal levels until.13 dpi (Fig. 3C, and data
not shown). Immunohistologic analyses revealed induced IDO
expression in the epithelial linings of a small number of bronchial
alveolar vesicles as early as 3 dpi, but only at local sites where
active influenza infection was also detected, as evidenced by
expression of influenza nucleoprotein (NP) in adjacent tissue
sections (Fig. 3D). Thus, IDO was induced rapidly in response to
local influenza infection, and IDO activity encoded exclusively by
IDO1 genes continued to increase during infection and remained
substantially higher than basal levels in lungs and msLNs long after
sterile virus clearance occurred. These data are consistent with
findings reported by Yoshida and colleagues who measured lung
IDO activity in ICR mice infected with PR8 [5], except that IDO
activity peaked later at ,11 dpi in this study.
Influenza infection induces IDO in distinct cell types in
lungs and msLNs
To evaluate if influenza infection induced IDO in hematopoi-
etic or non-hematopoietic cell compartments we lethally irradiated
IDO1-KO mice and reconstituted them with bone marrow from
B6 (WT) donor mice to generate B6RIDO1-KO chimeric mice.
After reconstitution (8 weeks) chimeric mice were infected with
X31 and IDO enzyme activity was assessed in lungs and msLNs.
IDO activity in lungs of infected B6RIDO1-KO chimeric mice
remained at basal levels, relative to uninfected controls (Fig. 3E,
open symbols). In contrast, IDO activity in msLNs from X31-
infected B6RIDO1-KO chimeric mice increased between 3–
11 dpi (Fig. 3E), and was comparable with increased IDO activity
observed in X31-infected B6 (WT) mice (Fig. 3B). Thus, non-
hematopoietic cells accounted for all lung IDO activity induced by
X31 infection, while hematopoietic cells accounted for all the IDO
activity induced in msLNs of X31-infected mice, indicating that
distinct cell types expressed IDO activity in these tissues.
Figure 2. IDO ablation enhances influenza-specific CD8 T cell responses to PR8 infection. B6 (WT) or IDO1-KO mice with B6 backgrounds
were infected with PR8 virus (50 PFU, i/n) at sub-lethal doses, and 10 days after infection bronchial alveolar lavage (BAL) cells and T cells were
counted. A. Representative FACS gating and analysis strategy to detect NP366-specific CD8 T cells using tetramers (upper panel) and intracellular
cytokine (IFNc, IL-10) expression after peptide specific stimulation for 2 hrs ex vivo (lower panel). B–F. Numbers of total BAL (B) and NP366 (C), PA (D),
PB1 (E) CD8 and NP311 (F) CD4 specific T cells. Data were analyzed using Student’s unpaired t test; *p,0.05, **p,0.01, ***p,0.001, ns, not significant.
doi:10.1371/journal.pone.0066546.g002
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Influenza induces IDO via distinct interferon signaling
pathways in lungs and msLNs
To assess IFN signaling requirements to induce IDO during
influenza infection mice lacking intact IFN type I (IFNAR-KO) or
type II (IFNcR1-KO) receptor genes were infected with X31 virus
and IDO activity was assessed in homogenized lungs and msLNs.
Throughout infection IDO activity remained at basal levels in
lungs of X31-infected IFNcR1-KO mice (Fig. 4A), relative to basal
IDO activity in lungs from uninfected mice (not shown), indicating
that IFNc induced IDO in infected lungs. In contrast, IDO
activity was induced to comparable levels in lungs of X31-infected
B6 and IFNAR-KO during influenza infection (Fig. 4A), indicat-
ing that IFNab signaling was not required to induce IDO in
infected lungs.
Ablating either IFN type I or type II receptors had no significant
effects on IDO activity in msLNs of X31-infected mice up to seven
days post-infection (Fig. 4B) when host adaptive immunity clears
virus from lungs in this model (Fig. 4C). Since IFN signaling is
essential to induce IDO gene transcription these findings suggest
that redundant signals from IFN types I or II induce IDO in this
period. In contrast, significantly lower IDO activity, relative to
WT controls, was observed in msLNs from X31-infected IFNcR1-
KO mice following virus clearance (7–9 dpi). Though IDO
activity levels were not significantly different (relative to WT mice)
in msLNs of X31-infected IFNAR-KO mice, IDO activity levels
were significantly higher in IFNAR-KO relative to IFNcR1-KO
mice in this period (Fig. 4B), emphasizing that IFNc is the major
IDO inducer in msLNs following virus clearance. Thus, unlike
lungs, where IFNc was essential to stimulate IDO activity during
and after infection, redundant IFN type I or type II signals up-
regulated IDO activity in msLNs during viral infection.
Virus titers in lungs at the peak of infection (3–6 dpi) were
significantly higher (6101–102) in IFNAR-KO mice than in B6
(WT) and IFNcR1-KO mice (Fig. 4C), indicating that IFN type I
mediated more effective virus control during X31 infection.
However, ablating either IFN type I or type II signaling led to
consistent delays in viral clearance (by one day), relative to virus
clearance rates in B6 (WT) mice (Fig. 4C). Rates of virus clearance
were unaffected by IDO1 gene ablation but virus titers in lungs
trended lower (though were not statistically significant) in IDO1-
KO mice (6101) relative to WT mice (Fig. 4C), suggesting that
IDO may impede host control during X31 infection.
IDO restrains host CD8 T cell responses to influenza
infection
To evaluate if IDO1 gene ablation affected host T cell responses
to influenza infection we assessed virus-specific CD8 T cell
responses in lungs and msLNs of B6 and IDO1-KO mice by flow
cytometric analyses. Total CD8 T cells specific for epitopes
Figure 3. Influenza A infection stimulates IDO in lungs and
draining msLNs. Mice were infected with 750 PFU of X31. IDO
expression and activity in lungs and msLNs were measured at the times
indicated after infection. ABE. Tissue kynurenine (A) or IDO enzyme
activity (B, E) were assessed in lungs and msLNs of X31-infected WT (B6),
IDO1-KO (B6) and B6RIDO1-KO chimeric mice. CD. IDO protein was
assessed in lungs of X31-infected WT mice by Western blot (C) and
immunohistochemical analyses (D). Influenza infected lung cells were
identified by detecting NP in adjacent sections (D). Data are the means
(+/21sd) of .3 mice/group from at least two independent exper-
iments. Original magnifications, 2006. **p,0.01, ***p,0.0001.
doi:10.1371/journal.pone.0066546.g003
Figure 4. Interferon signaling requirements to induce IDO. AB.
IDO enzyme activity was assessed in lungs (A) and msLNs (B) of WT (B6),
IFNAR-KO and IFNcR1-KO (B6) mice after X31-infection. C. Virus titers in
lungs of WT, IFNAR-KO and IFNcR1-KO mice. Statistical analyses were
performed on selected time points using Student’s unpaired t test.
*p,0.05, **p,0.01, ***p,0.001, Data were compiled from two
experiments with 2–6 mice/time point.
doi:10.1371/journal.pone.0066546.g004
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derived from NP366, PA and were comparable in BAL from X31-
infected B6 and IDO1-KO mice (Fig. S1). However msLNs in
infected IDO1-KO mice were consistently more inflamed, and
total cell numbers in msLNs were significantly higher (,3-fold)
than in B6 mice (Fig. 5A). Moreover, numbers of CD8 T cells
specific for NP366 and PA influenza epitopes were significantly
higher in msLNs (,2-fold) of IDO1-KO than B6 mice at 10 dpi,
indicating that IDO activity restrains clonal expansion of CD8
effector T cells in msLNs. These disparate outcomes for X31-
infected WT and IDO1-KO mice were remarkably similar to data
reported for PR8-infected mice, even though X31 infection had
almost no effect on host morbidity.
IDO shapes influenza-specific memory CD8 T cell
generation
To assess if IDO1 gene ablation influenced the generation of
memory CD8 T cells that protect mice from subsequent challenge
with lethal PR8 infection, B6 and IDO1-KO mice were primed
with X31 virus then challenged with a lethal dose of PR8 virus
(1006mLD50) .30 days after primary infection. CD8 T cell
responses to PR8 infection in BAL and lung parenchyma were
assessed by flow cytometry. Prior infection with X31 virus
protected B6 and IDO1-KO mice from lethal PR8 infection and
as expected, sterile viral (PR8) clearance occurred faster (5 dpi) in
both mouse strains (data not shown). Numbers of total cells,
NP366-specific, and PB1-specific CD8
+ T cells in BAL were
comparable between B6 and IDO1-KO mice (Fig. 6A–C), but
fewer total cells and NP366-specific and PB1-specific CD8
+ T cells
were found in lung parenchyma from PR8-infected IDO1-KO
mice (,2-fold less, Figs. 6A–C). Numbers of PA-specific CD8+ T
cells in BAL and lung parenchyma were comparable between B6
and IDO1-KO mice (data not shown). Thus, the exaggerated
primary NP366-specific CD8 T cell responses observed in IDO1-
KO mice infected with PR8 (Fig. 2) or X31 (Fig. 5) did not drive
exaggerated responses in X31-primed IDO1-KO mice challenged
with PR8.
In B6 mice long term NP366-specific memory CD8
+ T cells
exhibit dominant usage of Vb8.3 T cell receptor (TCR) chains
[29]. This hallmark feature was not evident when NP-specific CD8
T cells from IDO1-KO mice were analyzed (Fig. 6D). Proportions
of Vb8.3+ cells amongst memory CD8 NP366-specific T cells from
lung parenchyma were significantly lower in PR8-infected IDO1-
KO mice than in B6 mice (,4-fold) as evidenced by overall lower
absolute numbers (Fig. 6D) and decreased proportions (Fig. S2) of
Vb8.3+ T cells in the pool of NP366-specific CD8 T cells present in
lung parenchyma, though the proportions of Vb8.3+ CD8 NP366-
specific T cells in BAL from B6 and IDO1-KO mice were
comparable (Fig. 6D). Analyses of TCR Vb chain usage in long-
term memory CD8 NP366-specific splenic T cells 30 days after
PR8 challenge confirmed these findings (Fig. 6E) as the
proportions of gated NP366-specific memory CD8 T cells
Figure 5. IDO attenuates influenza-specific CD8 T cell responses in X31-infected mice. A–C. B6 and IDO1-KO (B6) mice were infected with
X31 virus and total numbers of cells and virus-specific CD8 T cell numbers were evaluated in msLNs at 10 dpi using tetramers specific for NP366 (B)
and PA (C). Data were compiled from 5 experiments, and statistical analyses were performed using Student’s unpaired t test; **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0066546.g005
Figure 6. IDO shapes influenza-specific memory CD8 T cell
generation. X31-primed WT and IDO1-KO (B6) mice were challenged
with PR8 and influenza-specific T cell responses in BAL and lung
parenchyma were assessed at 5 dpi. A–C. Numbers of total cells (A),
NP366-specific T cells (B), PB1-specific T cells (C). D. Repertoires of NP366-
specific T cells in BAL and lung parenchyma were analyzed by staining
cells for TCR Vb8.3 at 5 dpi. E. Repertoires of long-term NP366-specific
memory T cells in spleen were analyzed using a panel of antibodies
against various TCR Vb subtypes. Data were compiled from 2
experiments and statistical analyses were performed using Student’s
unpaired t test. *p,0.05, ****p,0.0001.
doi:10.1371/journal.pone.0066546.g006
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expressing Vb8.3 were significantly lower in spleens of immune
IDO1-KO mice (,10% Vb8.3+) relative to equivalent T cells
from immune B6 mice (,60% Vb8.3+), which was comparable
with previous reports [29,30]. This prominent repertoire shift
away from Vb8.3+ T cells in spleens of IDO1-KO mice did not
lead to quantitative differences in NP366-specific T cells (data not
shown). However, Vb TCR chain usage was comparable in
splenic CD8 T cells from IDO1-KO and B6 mice during primary
infection with X31 (Fig. S2), indicating that altered TCR Vb
repertoires were not a consequence of developmental differences
in T cell repertoires in IDO1-KO and B6 mice and arose due to
adaptive responses to X31/PR8 infection. Loss of dominant
Vb8.3+ NP-specific memory CD8 T cells did not lead to
compensatory increases in other Vb TCR isotypes detected by
the panel of anti-Vb TCR mAbs, suggesting that novel Vb TCR
sub-types emerged during recall responses, or that Vb8.3
dominant memory T cells failed to expand.
IDO attenuates lung TH17 responses during recall
responses to influenza infection
Lung IDO activity attenuates effector TH17 T cell responses
that drive lethal pathology during mycobacterial tuberculosis and
fungal aspergillosis [31,32]. To assess if IDO activity also regulated
TH17 responses X31-infected B6 and IDO1-KO mice were
challenged with PR8 and expression of IFNc and IL17a by CD4 T
cells in BAL and lung parenchymal cells from PR8-infected mice
was assessed after re-stimulation ex vivo (5 hr.+Brefeldin). Propor-
tions of CD4 T cells expressing IL17a were significantly higher in
BAL and lungs of IDO1-KO mice relative to B6 mice (Fig. 7A, B).
In contrast, proportions of CD4 T cells from PR8-infected B6 and
IDO1-KO mice that expressed IFNc were comparable (Fig. 7A,
C). Moreover, enhanced TH17 T cell responses did not manifest
during primary (sub-lethal) PR8 infection (Fig. S3), indicating that
exaggerated TH17 T cell responses after PR8 challenge were an
indirect consequence of ablating IDO activity during primary
(X31) infections.
Discussion
In this study we show that influenza infection stimulated rapid
increase in IDO activity in lungs and lung-associated lymph nodes
that persisted long after virus was eliminated from lungs. Ablating
IDO1 genes eliminated IDO activity in lungs and associated
lymph nodes, and loss of IDO activity led to less morbidity during
infection and faster recovery after viral clearance. More robust
primary CD8 and recall TH17 T cell effector responses also
manifested in lungs of infected mice lacking intact IDO1 genes,
and loss of IDO function altered the repertoire of virus-specific
memory CD8 T cells. Collectively, these findings reveal that
induced IDO contributes to increased morbidity and restrains and
shapes host T cell responses to influenza infection.
Influenza remains a leading cause of death in the US with
.53,000 deaths attributed by the CDC to influenza or influenza-
related infections in 2009 [33]. Many patients that die succumb to
secondary respiratory infections, such as pneumococcal infections,
due to reduced host resistance following primary influenza
infections. IDO was implicated as a potential host factor that
increases susceptibility to secondary lung infections as mice treated
with IDO inhibitor following primary influenza infection exhibited
more effective control of subsequent pneumococcal infections,
though increased host control of secondary infections did not
translate into lower mortality in this co-infection model [6].
Enhanced host susceptibility to secondary bacterial infections
manifested rapidly (as soon as 3 dpi) and can persist until long
after virus clearance [6,34]. In the present study, we found that
IDO ablation led to significant reduction in morbidity during
Figure 7. IDO attenuates TH17 responses to PR8 challenge. X31 primed WT and IDO1-KO (B6) mice were challenged with PR8 and CD4 T cell
status were assessed by FACS analysis of gated CD4 T cells in BAL and lung parenchyma at 5 dpi after ex vivo stimulation with PMA/ionomycin and
staining to detect intracellular cytokines. A. Representative FACS plots for intracellular staining of IL17a and IFNc in gated CD4 T cells. BC.
Percentages of IL17a (B) and IFNc+ (C) CD4 T cells are shown. Data were generated from mice primed from various times but re-challenged in the
same experiment (2–3/group). Data were analyzed using Student’s unpaired t test; **p,0.01, NS: non significant.
doi:10.1371/journal.pone.0066546.g007
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influenza infections, and to faster recovery after infections were
cleared. These findings support the hypothesis that elevated lung
IDO activity lowers resistance to opportunistic secondary infec-
tions that enhance morbidity, slow recovery, and increase the risk
of mortality. IDO activity also suppressed lung Th17 responses,
suggesting that IDO may attenuate collateral lung pathology
mediated by IL-17, as occurred in a model of pulmonary
aspergillosis [31]. Thus, IDO may alleviate cumulative lung
pathology caused by recurrent exposure to influenza in humans.
Sustained kynurenine release may also lower blood pressure and
drive ‘sickness induced depression’ syndromes that modify feeding
behaviors to confer potential survival advantages [35,36].
Of the two homologous genes that encode IDO enzymes in
mice [21], only the IDO1 gene encoded IDO activity induced by
influenza infection, and intact IDO2 genes did not compensate for
loss of IDO1 function in this setting. Similar to the study by
Yoshida and colleagues [5] infection with influenza PR8 and the
less virulent X31 strain stimulated rapid and substantial increase in
IDO activity in lungs that peaked about one week after initial
infection and persisted long after sterile viral clearance was
achieved. IDO expression was induced in lung epithelial cells from
early stages of infection (3 dpi) and was coincident with virus
infection. At such early stages of infection no virus-specific
lymphocytes were present in lungs to produce IFNc, the obligate
IDO inducer in lung stromal cells, suggesting that innate immune
cells such as macrophages and NK T cells may release IFNc in
response to initial influenza infection. Persistence of IDO activity
in the absence of direct viral stimulation at later stages after virus is
cleared from lungs may reflect continued IFN production or the
stability of IDO enzymes during the post-infection recovery phase.
Influenza infection stimulated IFN type I (IFNab) release to
comparable levels in lungs of mice (data not shown) that possessed
or lacked intact IFNc receptor genes, but IFNab did not induce
lung stromal cells to express IDO, suggesting that these cells are
unresponsive to signals from IFNab. In contrast, signals from
IFNab or IFNc induced IDO in hematopoietic cells in lung-
associated lymph nodes, suggesting that dendritic cells that express
IDO in response to signals from either IFNab or IFNc [37] may
account for IDO activity induced in these settings. Thus distinct
cell types in lungs or lung-associated lymph nodes expressed IDO
in response to IFN type I or type II signaling following influenza
infection.
IDO is induced by many microbial infections but has diametric
roles in both host defense and regulating host immunity [38]. IDO
mediates innate host defense to some pathogens by lowering the
viability of pathogen-infected cells and increasing resistance of
neighboring (uninfected) cells to pathogen infection [39,40]. If
IDO mediates host defense to influenza such functions were
dispensable, as IDO ablation did not compromise overall host
control of influenza infections. IDO also regulated host innate and
adaptive immunity in some mouse chronic respiratory infections,
such as tuberculosis and aspergillosis, to limit immune-mediated
collateral damage to lung tissues during such infections [31,32].
Moreover, the CD1d ligand alpha-galactosylceramide (aGalCer)
used as a natural killer (NK) T cell adjuvant to boost vaccine
responses had the paradoxical effect of reducing primary CD8 T
cell responses due to IDO induction, even though aGalCer
boosted long-term protective memory to influenza vaccination
[41]. In the present study we show that IDO attenuated virus-
specific CD8 T cell responses to primary influenza infection,
modified the repertoire of virus-specific, memory CD8 T cell
generated, and impaired lung TH17, but not TH1 responses
following PR8 challenge. However, the T cell regulatory effects
mediated by IDO did not compromise overall host control of virus
infection, slow viral clearance or reduce protective immunity to
PR8 challenge. Thus, IDO has nuanced effects on host T cell
primary responses to influenza infection, but IDO persistence
following viral clearance conditions lungs to be more susceptible to
secondary infections that enhance morbidity and the risk of
mortality. It is unclear what evolutionary benefits may counter the
apparent detrimental effects of induced IDO activity during
influenza infection but IDO-mediated innate host defense,
protection from collateral immune-mediated damage, and altered
behaviors are potential reasons why IDO activity is a prominent
feature of local host responses to influenza infection.
Supporting Information
Figure S1 Flu specific CD8 T cells in BAL after X31
infection. Numbers of NP366-specific (A) and PA-specific (B) T
cells in BAL were examined using MHC class I tetramers at
various times post infection (n = 3).
(TIFF)
Figure S2 IDO reduces NP366-specific memory CD8 T
cells expressing TCR Vb8.3+ in lung mesenchyma. A.
Mice were primed with PR8, challenged with X31 and tetramers
were used to gate NP366-specific CD8 T cells in lung parenchyma
and then assess surface TCR Vb8.3 expression. B. Vb8.3+ NP366-
specific splenic T cells were detected during X31 primary infection
at 8 dpi (B). *p,0.05, NS, not significant.
(TIFF)
Figure S3 IDO ablation does not affect Th1 or Th17
responses to primary PR8 infection. A. B6 (WT) and IDO1-
KO mice were infected with PR8 (200 PFU, i/n) and CD4 T cell
status in BAL and lung parenchyma at 8 dpi was assessed after ex
vivo stimulation with PMA/ionomycin and evaluating intracellular
cytokine staining by FACS analysis Representative FACS plots to
detect intracellular IFNc and IL-17a staining in CD4 T cells are
shown. BC. Proportions of IFNc (B) and IL-17a (C) producing
CD4 T cells in WT and IDO1-KO mice during primary PR8
infection (n= 3); NS, not significant.
(TIFF)
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